Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/dom.13301 http://scihub22266oqcxt.onion/10.1111/dom.13301 C6055757!6055757!29573529     free     free     free Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Diabetes+Obes+Metab 2018 ; 20 (8): 1988-93 Nephropedia Template TP {{tp|p=29573529|t=2018. Effects of the SGLT?2 inhibitor dapagliflozin on glomerular and tubular injury markers |pdf=|usr=}}{{29573529}} gab.com Text Effects of the SGLT 2 inhibitor dapagliflozin on glomerular and tubular injury markers JO: Diabetes Obes Metab http://www.kidney.de/pget.php?&tw=1&pmid=29573529 #FOAvip The mechanisms by which SGLT?2 inhibitors lower albuminuria are incompletely understood. We assessed in a post?hoc analysis of a cross?over trial the effects of the SGLT2 inhibitor dapagliflozin on glomerular markers (IgG to IgG4 and IgG to albumin), tubular markers (urinary KIM?1, NGAL and LFABP) and inflammatory markers (urinary MCP?1 and IL?6) to provide more insight into kidney protective effects. Dapagliflozin decreased albuminuria by 43.9% (95% CI, 30.3%?54.8%) and eGFR by 5.1 (2.0?8.1) mL/min/1.73m2 compared to placebo. Dapagliflozin did not change glomerular charge or size selectivity index compared to placebo. Dapagliflozin decreased urinary KIM?1 excretion by 22.6% (0.3%?39.8%; P?=?.05) and IL?6 excretion by 23.5% (1.4%?40.6%; P?=?.04) compared to placebo, whereas no changes in NGAL, LFABP and MCP?1 were observed. During dapagliflozin treatment, changes in albuminuria correlated with changes in eGFR (r?=?0.36; P?=?.05) and KIM?1 (r?=?0.39; P?=?.05). In conclusion, the albuminuria?lowering effect of 6 weeks of dapagliflozin therapy may be the result of decreased intraglomerular pressure or reduced tubular cell injury. Twit Text FOAVip Effects of the SGLT 2 inhibitor dapagliflozin on glomerular and tubular injury markers ????Diabetes Obes Metab http://www.kidney.de/pget.php?&tw=1&pmid=29573529 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29573529 #FOAvip English Wikipedia <ref>{{Cite pmid|29573529}}</ref> Effects of the SGLT?2 inhibitor dapagliflozin on glomerular and tubular injury markers #MMPMID29573529 Dekkers CCJ; Petrykiv S; Laverman GD; Cherney DZ; Gansevoort RT; Heerspink HJL Diabetes Obes Metab 2018[Aug]; 20 (8): 1988-93 PMID29573529show ga The mechanisms by which SGLT?2 inhibitors lower albuminuria are incompletely understood. We assessed in a post?hoc analysis of a cross?over trial the effects of the SGLT2 inhibitor dapagliflozin on glomerular markers (IgG to IgG4 and IgG to albumin), tubular markers (urinary KIM?1, NGAL and LFABP) and inflammatory markers (urinary MCP?1 and IL?6) to provide more insight into kidney protective effects. Dapagliflozin decreased albuminuria by 43.9% (95% CI, 30.3%?54.8%) and eGFR by 5.1 (2.0?8.1) mL/min/1.73m2 compared to placebo. Dapagliflozin did not change glomerular charge or size selectivity index compared to placebo. Dapagliflozin decreased urinary KIM?1 excretion by 22.6% (0.3%?39.8%; P?=?.05) and IL?6 excretion by 23.5% (1.4%?40.6%; P?=?.04) compared to placebo, whereas no changes in NGAL, LFABP and MCP?1 were observed. During dapagliflozin treatment, changes in albuminuria correlated with changes in eGFR (r?=?0.36; P?=?.05) and KIM?1 (r?=?0.39; P?=?.05). In conclusion, the albuminuria?lowering effect of 6 weeks of dapagliflozin therapy may be the result of decreased intraglomerular pressure or reduced tubular cell injury. äEffects of the SGLT?2 inhibitor dapagliflozin on glomerular and tubula(epmc).pdf DeepDyve Pubget Overpricing